BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences

LYNBROOK, N.Y., Sept. 2, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX^® in the U.S. and Xiapex^® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the following upcoming conferences.

• NewsMakers in the Biotech Industry Conference at 9:00 a.m. ET on Friday, September 9, 2016 in New York, NY. Link: http://wsw.com/webcast/biocentury3/bstc.
• Rodman & Renshaw 18th Annual Global Investment Conference at 4:40 p.m. ET on Monday, September 12, 2016 in New York, NY. Link: http://wsw.com/webcast/rrshq26/bstc

A live audio webcast of each presentation can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com. An archived replay of the webcast will be available for 30 days after the live event concludes.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and also for Peyronie's disease in Europe and Australia. Endo has the following partnerships outside the U.S. for these two indications; Swedish Orphan Biovitrum AB has marketing rights for Xiapex® (the European tradename for XIAFLEX) in 71 Eurasian and African countries, Actelion Pharmaceuticals Ltd. has marketing rights in Canada and Australia and Asahi Kasei Pharma Corporation has marketing rights in Japan. Sobi is selling Xiapex in Europe for the treatment of Dupuytren's contracture and Peyronie's disease. Asahi is selling XIAFLEX for the treatment of Dupuytren's contracture in Japan. Actelion is selling XIAFLEX in Canada and Australia for the treatment of Dupuytren's contracture and in Australia for Peyronie's disease. The XIAFLEX development pipeline includes several additional promising indications. Endo is currently managing development of CCH for cellulite, adhesive capsulitis, human and canine lipoma, lateral hip fat and plantar fibromatosis. BioSpecifics is managing the development of CCH for uterine fibroids and plans to initiate clinical development in the second half of 2016. For more information, please visit www.biospecifics.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-two-upcoming-september-conferences-300318721.html

SOURCE BioSpecifics Technologies Corp.